BLUE.O
Latest Trade
7.24USDChange
--(--)Today's Range
-
--52 Week Range
-
48.92As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 7.24 |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 46.16 |
Today's High | -- |
Today's Low | -- |
52 Week High | 48.92 |
52 Week Low | 6.75 |
Shares Out (MIL) | 70.11 |
Market Cap (MIL) | 485.84 |
Forward P/E | -0.60 |
Dividend (Yield %) | -- |
bluebird Bio Inc - Full-Year 2022 Cash Burn Is Expected To Be Less Than $400 Million
bluebird Bio Inc - Full-Year 2022 Cash Burn Is Expected To Be Less Than $400 Million
Bluebird Bio Announces Partial Clinical Hold For Patients Under 18 In Sickle Cell Gene Therapy Clinical Program
bluebird bio, Inc. is a biotechnology company. The Company is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s programs in genetic diseases include betibeglogene autotemcel (beti-cel) as a treatment for transfusion-dependent B-thalassemia (TDT); LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). It develops LentiGlobin gene therapy for patients with SCD, a hereditary blood disorder resulting from a mutation in the b-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. The beti-cel is marketed as ZYNTEGLO for the treatment of adult and adolescent patients with TDT in the European Union. Its product candidate also include SKYSONA for the treatment of patients with CALD in the European Union, Iceland, Liechtenstein and Norway.
Industry
Biotechnology & Drugs
Contact Info
60 Binney St
CAMBRIDGE, MA
02142-1512
United States
+1.339.4999300
http://www.bluebirdbio.comExecutive Leadership
Andrew Obenshain
President, Chief Executive Officer, Director
Gina Consylman
Chief Financial Officer
Jessica Whitten
Chief Accounting Officer
Jason F Cole
Chief Business Officer
Thomas J. Klima
Chief Commercial Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 9.06 |
Price To Book (MRQ) | 0.56 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -61.25 |
Return on Equity (TTM) | -52.61 |
Bluebird bio Inc said on Monday its gene therapy trial for sickle cell disease has been placed on partial hold for children while the company investigates the potential side-effect of persistent anemia in a patient.
Bluebird bio Inc < BLUE.O> said on Monday it has set at $419,500 the wholesale list price of its newly approved multiple myeloma therapy developed with Bristol-Myers Squibb Co.
Bluebird bio Inc plans to spin off its cancer drugs unit into a new, publicly traded company later this year to focus on rare genetic diseases, the company said on Monday.
Bluebird bio Inc plans to spin off its cancer drugs unit into a new, publicly traded company later this year, the Wall Street Journal reported on Monday.
Bluebird bio Inc <BLUE.O> said on Monday Bristol Myers Squibb Co <BMY.N> would give it a one-time payment of $200 million to buy out obligations for future royalties on sales outside the United States of two cancer therapies being developed by them.
Bluebird bio Inc said on Monday partner Bristol Myers Squibb Co would pay $200 million to buy out future royalty obligations on sales of two therapies being developed by the companies.
* BLUEBIRD BIO ANNOUNCES AMENDED BCMA CAR-T COLLABORATION AGREEMENT
* BLUEBIRD BIO INC - NICK LESCHLY, CO'S CHIEF EXECUTIVE OFFICER, REDUCED HIS BASE SALARY BY APPROXIMATELY 100% DURING THIS TWELVE-MONTH PERIOD
* BLUEBIRD BIO PROVIDES ASSESSMENT OF IMPACT OF COVID-19, UPDATE ON BUSINESS OPERATIONS AND CLINICAL PROGRAM DEVELOPMENT
* BLUEBIRD BIO - ON MARCH 6, CO'S UNIT AND APCETH BIOPHARMA GMBH ENTERED INTO AMENDMENT
Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.
Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.
Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.
A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.
A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.